Article
American Medical Systems, Inc. has received FDA approval for the AMS 700 with Inhibizone as the only inflatable penile prosthesis with clinical evidence showing a significant reduction in the rate of revision surgery due to infection.
American Medical Systems, Inc. has received FDA approval for the AMS 700 with Inhibizone as the only inflatable penile prosthesis with clinical evidence showing a significant reduction in the rate of revision surgery due to infection.
The AMS 700 with Inhibizone elutes a proprietary combination of minocycline hydrochloride and rifampin from its silicone surfaces. Based on nearly 7 years of post-market study data from more than 40,000 patients implanted with the devices, the FDA agreed that the use of the drug-eluting prosthesis resulted in a significantly reduced rate of revisions due to infection in patients receiving both a first-time AMS 700 implant or revision implant.
In diabetic patients, who are at an increased risk of infection, the post-market study also concluded that the use of Inhibizone-treated penile prosthesis resulted in a significant reduction in the rate of revisions due to infection in those receiving a first-time AMS 700 implant.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Study shows persistent bone protective effect of menopausal hormone therapy
Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC
Aquablation procedures for prostate cancer completed at ambulatory surgery center
FDA grants priority review to expanded indication of flibanserin in HSDD
2 Commerce Drive
Cranbury, NJ 08512